Capricor Therapeutics Inc. designed its Duchenne muscular dystrophy (DMD) trial to fit “exactly what the FDA has now mandated they want” in the troubled space, CEO Linda Marbán told BioWorld Today, and the firm’s CAP-1002 represents “a novel take and a practical approach” to the disease.